File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction

TitleEsomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction
Authors
Issue Date2012
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2012, v. 107 n. 3, p. 389-396 How to Cite?
AbstractObjectives: Little is known about the efficacy of proton pump inhibitors compared with H 2 receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics. The objective of this study was to compare the efficacies of esomeprazole and famotidine in preventing gastrointestinal complications. Methods: A double-blind, randomized, controlled trial was performed in patients receiving a combination of aspirin, clopidogrel, and either enoxaparin or thrombolytics. Patients received either esomeprazole (20 mg nocte) or famotidine (40 mg nocte) orally for 4-52 weeks, depending on the duration of dual antiplatelet therapy. The primary end point was upper gastrointestinal bleeding (GIB), perforation, or obstruction from ulcer/erosion (http://www.clinicaltrials.gov NCT00683111). Results: In all, 311 patients were recruited, with 163 and 148 patients in the esomeprazole and famotidine groups, respectively. Mean (s.d.) follow-up was 19.2 (17.6) and 17.6 (18.0) weeks, respectively. One (0.6%) patient in the esomeprazole group and 9 (6.1%) in the famotidine group reached the primary end point (log-rank test, P=0.0052, hazard ratio0.095, 95% confidence interval: 0.005-0.504); all had upper GIB. Conclusions: In patients with ACS or STEMI, esomeprazole is superior to famotidine in preventing upper gastrointestinal complications related to aspirin, clopidogrel, and enoxaparin or thrombolytics. © 2012 by the American College of Gastroenterology.
Persistent Identifierhttp://hdl.handle.net/10722/163464
ISSN
2014 Impact Factor: 10.755
2014 SCImago Journal Rankings: 3.376
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, FHen_HK
dc.contributor.authorTunggal, Pen_HK
dc.contributor.authorChu, WMen_HK
dc.contributor.authorLam, KFen_HK
dc.contributor.authorLi, Aen_HK
dc.contributor.authorChan, Ken_HK
dc.contributor.authorLau, YKen_HK
dc.contributor.authorKng, Cen_HK
dc.contributor.authorKeung, KKen_HK
dc.contributor.authorKwan, Aen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2012-09-05T05:31:43Z-
dc.date.available2012-09-05T05:31:43Z-
dc.date.issued2012en_HK
dc.identifier.citationAmerican Journal Of Gastroenterology, 2012, v. 107 n. 3, p. 389-396en_HK
dc.identifier.issn0002-9270en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163464-
dc.description.abstractObjectives: Little is known about the efficacy of proton pump inhibitors compared with H 2 receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics. The objective of this study was to compare the efficacies of esomeprazole and famotidine in preventing gastrointestinal complications. Methods: A double-blind, randomized, controlled trial was performed in patients receiving a combination of aspirin, clopidogrel, and either enoxaparin or thrombolytics. Patients received either esomeprazole (20 mg nocte) or famotidine (40 mg nocte) orally for 4-52 weeks, depending on the duration of dual antiplatelet therapy. The primary end point was upper gastrointestinal bleeding (GIB), perforation, or obstruction from ulcer/erosion (http://www.clinicaltrials.gov NCT00683111). Results: In all, 311 patients were recruited, with 163 and 148 patients in the esomeprazole and famotidine groups, respectively. Mean (s.d.) follow-up was 19.2 (17.6) and 17.6 (18.0) weeks, respectively. One (0.6%) patient in the esomeprazole group and 9 (6.1%) in the famotidine group reached the primary end point (log-rank test, P=0.0052, hazard ratio0.095, 95% confidence interval: 0.005-0.504); all had upper GIB. Conclusions: In patients with ACS or STEMI, esomeprazole is superior to famotidine in preventing upper gastrointestinal complications related to aspirin, clopidogrel, and enoxaparin or thrombolytics. © 2012 by the American College of Gastroenterology.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_HK
dc.relation.ispartofAmerican Journal of Gastroenterologyen_HK
dc.subject.meshAcute Coronary Syndrome - Complications - Drug Therapyen_US
dc.subject.meshAgeden_US
dc.subject.meshAnti-Ulcer Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAspirin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEnoxaparin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshFamotidine - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFibrinolytic Agents - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGastrointestinal Hemorrhage - Chemically Induced - Prevention & Controlen_US
dc.subject.meshHumansen_US
dc.subject.meshIntestinal Perforation - Etiology - Prevention & Controlen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOmeprazole - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshPlatelet Aggregation Inhibitors - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshProportional Hazards Modelsen_US
dc.subject.meshTiclopidine - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleEsomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarctionen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, KF: hrntlkf@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityLam, KF=rp00718en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/ajg.2011.385en_HK
dc.identifier.pmid22108447-
dc.identifier.scopuseid_2-s2.0-84857910372en_HK
dc.identifier.hkuros205590-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857910372&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume107en_HK
dc.identifier.issue3en_HK
dc.identifier.spage389en_HK
dc.identifier.epage396en_HK
dc.identifier.eissn1572-0241-
dc.identifier.isiWOS:000301496600008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f100013399004-
dc.identifier.scopusauthoridNg, FH=16936078000en_HK
dc.identifier.scopusauthoridTunggal, P=54394619800en_HK
dc.identifier.scopusauthoridChu, WM=23995209500en_HK
dc.identifier.scopusauthoridLam, KF=8948421200en_HK
dc.identifier.scopusauthoridLi, A=54395805400en_HK
dc.identifier.scopusauthoridChan, K=36915726100en_HK
dc.identifier.scopusauthoridLau, YK=35765428400en_HK
dc.identifier.scopusauthoridKng, C=7801364659en_HK
dc.identifier.scopusauthoridKeung, KK=6508135342en_HK
dc.identifier.scopusauthoridKwan, A=55223335800en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats